National and Kapodistrian University of Athens
Μελέτη αναπαραγωγικού, νευροενδοκρινικού και μεταβολικού προφίλ σε παιδιά και εφήβους με κακοήθεια μετά το πέρας της θεραπείας σε σύγκριση με υγιείς μάρτυρες
Abstract
dc:descriptionObjective: To assess the metabolic profile and reproductive function of children and adolescents survivors of childhood cancer (CCS), comparing them with healthy controls, and to explore potential changes in these markers over time. Additionally, the study aims to determine and compare the concentrations of adipokines (lipokines) in the serum of both groups and investigate any relationship between these markers and metabolic and reproductive indicators. Materials and Methods: The study included children and adolescents aged 8–18 years, survivors of cancer, at least 6 months after completing treatment for cancer, and an age-matched group of healthy controls. Participants were clinically examined at two time points (0 and 9 months after the initial evaluation). A comprehensive metabolic and reproductive profile was obtained, and body composition was assessed using bioelectrical impedance. Serum adipokine concentrations were measured using the ELISA immunoassay method. Results: A total of 130 participants were included in the study, with a mean age of 12.81 ± 3.27 years. Of the participants, 77 were CCS (48.1% male) and 53 were healthy controls (45.3% male). The participants were matched for sex, age, and pubertal stage (p>0.05). Among the CCS group, 42% were diagnosed with acute lymphoblastic leukemia (ALL), 20% with Hodgkin lymphoma, 11% with non-Hodgkin lymphoma, 9.5% with brain tumors, 4% with acute myelogenous leukemia (AML), 5.5% with nephroblastoma, and 8% with other malignancies. The mean age at diagnosis was 9.62 ± 3.86 years, and the mean time since completing treatment was 21 months.No statistically significant differences were found between the two groups in body mass index (BMI) (p=0.139), skeletal mass (SM) (p=0.914), and adipose tissue (AT) (p=0.937). However, the CCS group had higher levels of γ-glutamyl transferase (γGT) (p=0.048), triglycerides (TG) (p=0.003), C-reactive protein (CRP) (p=0.001), and parathyroid hormone (PTH) (p=0.025), while lower levels of morning cortisol (p=0.008) and prolactin (PRL) (p=0.035) were observed. Age at cancer diagnosis was positively correlated with BMI (p<0.001) and waist circumference (WC) (p<0.001). A significant negative correlation was found with HDL (p<0.05) and apolipoprotein A1 (Apo-A1) (p<0.001), while a positive correlation with uric acid (UA) was observed (p<0.01). In CCS patients who received anthracyclines, higher glucose levels were found (p= 0.037).CCS had lower levels of irisin compared to healthy controls (p=0.039). A negative correlation between irisin and age, as well as CRP, was observed, and a positive correlation with alkaline phosphatase (ALP) (p<0.05) was found. Multivariate linear regression analysis showed that PTH was the only independent variable affecting serum irisin concentrations. There were no significant differences in adiponectin and resistin levels between the two groups (p=0.177 and p=0.258, respectively). Adiponectin levels were significantly higher in normal- weight participants (p=0.03) and prepubertal children (p=0.006). Strong negative correlations with BMI, WC, and hip circumference were observed, with more pronounced associations in the survivors (p<0.001). Regarding the lipid profile, adiponectin was positively correlated with HDL (<0.001) and Apo-A1 (p<0.01) and negatively correlated with TG (p<0.05) and UA (p<0.001). It also showed a significant positive correlation with extracellular water percentage (ECW%) and a negative correlation with intracellular water percentage (ICW%).Regarding the hormonal profile, adiponectin was positively correlated with sex hormone-binding globulin (SHBG) (p<0.01) and negatively correlated with total testosterone (p<0.05), DHEAS, 17- hydroxyprogesterone, and cortisol (p<0.05). Additionally, adiponectin showed a significant negative correlation with age at cancer diagnosis (p<0.01).Resistin was positively correlated with age (p<0.001), with girls and adolescents showing higher levels (p=0.03 and p=0.019). Positive correlations were found between resistin and BMI, WC, fat mass (FM%), visceral fat (AT%), and intramuscular adipose tissue (IMAT kg) in the entire sample (p<0.01), and a negative correlation with fat-free mass (FFM%) was observed. In the lipid profile, resistin showed positive correlations with TG (p<0.05) and UA (p<0.05) and a negative correlation with HDL in CCS (p<0.05). A positive correlation was also found between resistin and diastolic blood pressure (p<0.001). Negative correlations were observed with ALP (p<0.001). Resistin also showed a significant positive correlation with age at cancer diagnosis (p<0.05).At the 9-month follow-up, significant decreases in γGT (p=0.022), SHBG (p=0.003), and PTH (p=0.01) levels were observed in the CCS group, while a significant increase in IGF-I levels was recorded (p=0.004).Regarding the overall changes over time between the two groups, statistically significant results were found for changes in SHBG (p=0.006), TG (p=0.016), QUICKI (p<0.001), 17-OH-progesterone (p=0.029), ALP (p=0.046), and TSH (p=0.038). Conclusions: The preservation of skeletal muscle mass and adipose tissue after treatment in childhood cancer survivors is a favorable finding for the patients, suggesting increased plasticity and adaptability of these tissues during childhood and adolescence. Higher serum adiponectin levels were associated with a more favorable cardiometabolic profile, while higher resistin levels were associated with an unfavorable profile. Serum irisin levels differed significantly between CCS and healthy controls and associated with PTH. Future studies are needed to clarify the potential role of irisin as a biomarker of bone status in childhood cancer survivors during childhood and adolescence. Additionally, monitoring SHBG levels and the QUICKI insulin sensitivity index may be important prognostic indicators for identifying CCS at increased cardiometabolic risk. Larger-scale studies, involving survivors of various types of cancer, are needed to confirm and further explore these findings.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Apostolaki, Despoina
- Αποστολάκη, Δέσποινα
Subjects
dc:subject × 18- Επιβιώσαντες από καρκίνο
- Παιδιά
- Έφηβοι
- Αδιπονεκτίνη
- Ρεζιστίνη
- Ιρισίνη
- Childhood cancer survivors
- Children
- Adolescents
- Adiponectin
- Resistin
- Irisin
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ενδοκρινολογία, Διαβήτης και Μεταβολισμός
- Clinical Medicine
- Medical and Health Sciences
- Endocrinology, Diabetes and Metabolism
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60469